Salbutamol Oral Liquid Market Report 2026

The salbutamol oral liquid market size has grown strongly in recent years. It will grow from $1.17 billion in 2025 to $1.24 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to limited availability of salbutamol oral liquid formulations, reliance on hospital pharmacy distribution, increasing awareness of respiratory disease management, adoption of standard syrup and solution forms, conventional manufacturing techniques.

The salbutamol oral liquid market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to development of advanced oral liquid suspensions, growing online pharmacy penetration, rising pediatric and geriatric patient base, expansion of multi-ingredient respiratory formulations, increasing regulatory compliance and quality certifications. Major trends in the forecast period include rising prevalence of asthma and copd, increasing demand for pediatric and geriatric formulations, expansion of hospital and retail pharmacy channels, growth in online pharmacy and e-commerce distribution, focus on preservative-free and patient-friendly formulations.

The increasing incidence of respiratory disorders is expected to drive the growth of the salbutamol oral liquid market in the coming years. Respiratory disorders are medical conditions that affect the lungs and airways, leading to impaired breathing and reduced oxygen exchange in the body. The rising incidence of respiratory disorders is largely attributed to increasing air pollution and exposure to environmental pollutants. Salbutamol oral liquid is used in the treatment of respiratory disorders to relax airway muscles, relieve bronchospasms, and improve airflow, thereby reducing symptoms such as wheezing, shortness of breath, and chest tightness. For instance, in October 2025, according to the Australian Bureau of Statistics, an Australia-based government agency, deaths involving influenza increased from 611 in 2023 to 806 in 2024 and further to 1,057 deaths in the year to August 2025, representing a 73% rise from 2023 to the comparable August 2025 period. Additionally, deaths involving respiratory syncytial virus (RSV) rose from 380 in 2023 to 468 in 2024 and 399 in the year to August 2025. Therefore, the increasing incidence of respiratory disorders is driving the growth of the salbutamol oral liquid market.

The rise in air pollution is expected to propel the growth of the salbutamol oral liquid market going forward. Air pollution refers to the presence of harmful substances in the atmosphere that adversely impact human health, the environment, and the climate. Increasing air pollution is mainly driven by higher emissions from industrial activities and the combustion of fossil fuels. Salbutamol oral liquid helps relieve breathing difficulties caused by air pollution by relaxing airway muscles and enhancing airflow to the lungs. For instance, in August 2025, according to the Energy Policy Institute at the University of Chicago (EPIC), a US-based interdisciplinary research institute, data from 2023 showed that global particulate matter concentrations in the air were 1.5% higher than in 2022. Therefore, the rise in air pollution is driving the growth of the salbutamol oral liquid market.

The increase in healthcare expenditures is expected to propel the growth of the salbutamol oral liquid market going forward. Healthcare expenditures refer to the total spending on healthcare services and products, including hospital care, physician services, medications, and public health initiatives. Rising healthcare expenditures are often driven by the increasing costs of advanced medical technologies and treatments. Higher healthcare spending supports the salbutamol oral liquid market by improving access to essential respiratory medications, enabling broader diagnosis and treatment of asthma and COPD, and allowing healthcare systems to stock and distribute bronchodilators more effectively, particularly in resource-limited settings. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, a notable rise compared to the 0.9% growth recorded in 2022. Therefore, the rise in healthcare expenditures is driving the growth of the salbutamol oral liquid market.

Major companies operating in the salbutamol oral liquid market are GlaxoSmithKline plc, Cipla Limited, Lupin Limited, Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Limited, Beta Healthcare International Limited, Sakar Healthcare Limited, Pharmatec Pakistan (Private) Limited, Infinity Pharma, Azaria Pharmaceutical Laboratories Inc., Salvavidas Pharmaceutical Private Limited, Lucky Pharmaceuticals, Wellona Pharma, Centurion Healthcare Private Limited, Niksan Pharmaceutical, SUNWARD PHARMACEUTICAL SDN. BHD., Glumex Pharmaceuticals Mfg. Pvt. Ltd., Indo Rama Engineers, Elikem Pharmaceuticals Private Limited, CCI Products.

North America was the largest region in the salbutamol oral liquid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the salbutamol oral liquid market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the salbutamol oral liquid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the salbutamol oral liquid market by increasing costs for imported raw materials and excipients used in syrup and suspension formulations. Segments such as oral liquid suspensions with preservatives and multi-ingredient formulations are particularly affected, with regions like Asia-Pacific, including India and China, experiencing higher import duties. While tariffs have caused cost pressures and supply chain adjustments, they have also encouraged local production, innovation in preservative-free formulations, and greater investment in domestic manufacturing facilities.

The salbutamol oral liquid market research report is one of a series of new reports that provides salbutamol oral liquid market statistics, including salbutamol oral liquid industry global market size, regional shares, competitors with a salbutamol oral liquid market share, detailed salbutamol oral liquid market segments, market trends and opportunities, and any further data you may need to thrive in the salbutamol oral liquid industry. This salbutamol oral liquid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Salbutamol oral liquid is a pharmaceutical formulation that contains salbutamol, a bronchodilator that works by relaxing the airway muscles. It is used to relieve and prevent bronchospasm in respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The main product types of salbutamol oral liquid include oral liquid solutions and oral liquid suspensions. Salbutamol oral liquid solutions are bronchodilator preparations in liquid form that are mainly used to alleviate symptoms of asthma, bronchitis, and other obstructive airway disorders by relaxing airway muscles and improving airflow to the lungs. These formulations include syrups, solutions, and concentrates and may contain active ingredients such as albuterol, levalbuterol, pirbuterol, salmeterol, and formoterol. Salbutamol oral liquids are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used for applications including asthma, chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

The salbutamol oral liquid market consists of sales of ventolin syrup, asthalin syrup, salbetol syrup, bronkotab syrup, salbulin syrup, ventair syrup. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.